Allogeneic hematopoietic stem cell transplantation could improve survival for pure CBF-AML patients with minimal residual disease positive after the second consolidation

Abstract

The role of MRD-directed risk stratification strategy for core binding factor acute myeloid leukemia (CBF-AML) patients with favorable risk genetics is still unknown. We retrospectively analyzed the clinical outcomes of 148 pure CBF-AML patients with first complete remission including MRD positive (n = 69) and MRD negative (n = 79) after two courses of consolidation from January 2009 to December 2018 in our center. We found that MRD positive after 2 courses of consolidation significantly influenced OS (5-year: 59%), PFS (5-year: 36%) and CIR (5-year: 58%) in favorable-risk CBF-AML patients with CR1. It was worth noting that the MRD status after two courses of consolidation might be the best timing for treatment choice and allo-HSCT was a promising treatment for favorable-risk CBF-AML patients with MRD positive after the second consolidation.

Keywords:

• Core binding factor acute myeloid leukemia
• allogeneic hematopoietic stem cell transplantation
• minimal residual disease
• clinical outcomes
• prognostic factors

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

This work was supported by grants from the National Natural Science Foundation of China [81730003, 81870120], the Natural Science Foundation of Jiangsu Province [BK20171205], the Social Development Project of Jiangsu Province [BE2019655], the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD), and the National Key Research and Development Program [2017ZX09304021, 2017YFA0104500, 2019YFC0840604]. All the samples were obtained from the Jiangsu Biobank of Clinical Resources.